R ecommendations for high risk populations by the Advisory Committee on Immunization Practices (ACIP) for the prevention and control of influenza have consistently included older adults (older than 65 years), those in institutionalized care (e.g., nursing homes, chronic-care facilities), children and adults with chronic health conditions, pregnant women past the first trimester of gestation during the influenza season, and health care providers. Additional recommendations now include children younger than 24 months because of their increased risk for influenza-related hospitalizations and adults ages 50 to 64 because of their greater prevalence of high-risk health conditions. Twenty-nine percent of adults ages 50 to 64 are estimated to have one or more high-risk health conditions (ACIP, 2003) :
The ACIP (2003) recommends research related to the relative cost effectiveness and cost utility of influenza vaccinations among working adults. The purpose of this review is to summarize the current literature related to cost-benefit evaluations of worksite influenza immunization and offer insights into the implementation of an employee influenza immunization program at a large company. The reader is referred elsewhere for evaluations of influenza immunization practices and cost effectiveness in other population settings (e.g., young children, older adults, chronically ill) (Principi, Esposito, Marchisio, Gasparini, & Crovari, 2003; Terebuh, Uyeki, Fukuda, 2003 
INFLUENZA OVERVIEW
Person-to-person transmission of the virus occurs by aerosolized droplets primarily through the coughing and sneezing of infected persons (Cox & Subbarao, 1999) . Average incubation period is 2 days (range 1 to 4 days) with potential contagion from 24 hours prior to the onset of symptoms to 5 days after. Uncomplicated illness in working adults occurs quickly with fever, myalgia, headache, malaise, nonproductive cough, sore throat, and rhinitis as the predominant signs and symptoms (Couch, 2000) . Human influenza is unlikely to be eradicated because of the reservoir of viral subtypes in wild aquatic birds that can cross host species.
Influenza viruses are negative-strand RNA viruses from the Orthomyxoviridae family of which Type A and B cause epidemic human disease (Cox & Subbarao, 1999) . Influenza A viruses are divided into subtypes based on serologic and genetic differences in surface glycoproteins (antigens)-hemaglutinin (H) and neuraminidase (N). A total of 15 subtypes of hemaglutinin (H I to HIS) and nine subtypes of neuraminidase (Nl to N9) have been identified. Influenza B viruses are not categorized into subtypes. The World Health Organization (WHO) nomenclature specifies type, geographic source, strain number, and year of isolation to which code designations of hemaglutinin and neuraminidase subtypes are added.
Inactivated (killed) influenza vaccines are prepared from viruses grown in chick embryos. For this reason, the vaccine is contraindicated for individuals who are hypersensitive to eggs. The material is standardized to contain 15 ug of the hemaglutinin protein 'of each virus per vaccine dose. Selection of the viruses to be vaccinated is determined annually by the U.S. Food and Drug Admin-istration (FDA) and is based on the occurrence of suspected new antigenic drift virus(es), assessment of antibody levels against the new virus in serum samples from individuals recently vaccinated, and availability of a high-yield strain for production of vaccine (Cox & Subbarao, 1999 (FDA, 2004) .
Currently, there are only two vaccine distributors of trivalent inactivated vaccines given intramuscularly: Chiron Corporation in Emeryville, California (Fluvirin") and Aventis-Pasteur in Swiftwater, Pennsylvania (Fluzone"), Chiron Corporation notified the U.S. Centers for Disease Control and Prevention (CDC) that none of its influenza vaccine would be available for distribution in the Recently available is trivalent live cold adopted influenza vaccine (LAIV-T) (FluMist®, Medlmmune Vaccines, Inc., Gaithersburg, MD), administered intranasally. Itis reported to be an effective means to prevent influenza in adults (Nichol et aI., 1999; Treanor et al., 2000) . LAIV-T is also developed in chick-embryo cells. Unlike the inactivated vaccines, LAIV-T is currently not recommended for adults ages 50 and older, thereby reducing some of its practical usefulness in the workplace setting. It is also not recommended for individuals (health care professionals or family members) who may be in contact with immunosuppressed individuals.
COST-BENEFIT ANALYSES OF WORKSITE INFLUENZA IMMUNIZATION PROGRAMS
Cost-benefit analysis compares the benefits of a course of action (e.g., offer by an employer to immunize employees for influenza at the worksite) to the costs associated with the course of action. Cost-benefit analysis can measure actual financial data as well as estimate costs and benefits through model assumptions. The latter may introduce more subjective measurements, but can be evaluated by sensitivity assessments.
The present review is limited to those published studies in the literature since the 1990s that have evaluated the cost-benefit of worksite influenza immunization programs via randomized double-blind, placebo-controlled trials in non-health care workplace settings (N =2 studies) and cost-benefit models (N =4 studies). A summary of these studies is found in the Table. Randomized, double-blind, placebo-controlled trials in health care settings (Saxen & Virtanen, 1999; Weingarten et aI., 1988; Wilde et al., 1999) were not reviewed because these workplace populations are already included in the ACIP guidance for influenza immunizations.
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There are also many retrospective assessments of the effectiveness of worksite influenza immunization programs that are not presented because of their variability in study methodologies, potential for unmeasured study biases, and often small study populations. Other authors have provided informative descriptive reviews of several of these retrospective assessments (Postma et aI., 2002; Wood, Van Hung, & Schmidt, 2000) . Nichol et aI. (1995) conducted a randomized, double-blind, placebo-controlled trial of influenza vaccination effectiveness in a population of 849 healthy working adults (11 = 425 and 424 placebo and vaccine groups, respectively) ages 18 to 64 at the time (fall 1994) with 63% women. Participants in the placebo group received a diluent vaccination. Five follow-up structured telephone interviews were completed with 99% of the participants from 7 to 14 days after immunization to 5 months later. The only side effect significantly associated with administration of the influenza vaccine was arm soreness (64% vs. 24% for placebo, p < .001).
TRIALS OF NON-HEALTH CARE WORKSITES
The effectiveness of the influenza vaccine contributed to 25% fewer episodes of influenza-like symptoms, 43% fewer sick leave days, and 44% fewer physician visits due to upper respiratory illnesses. Direct costs included cost per vaccination, health care for side effects, and health care savings due to avoided treatment of upper respiratory illnesses. Indirect costs included lost work time for vaccination (estimated at 30 minutes per person), work loss due to side effects, and work loss avoided. Net savings was estimated at $46.85 (1995 dollars) and Nichol et al. (1995) concluded that influenza vaccination of healthy adults results in substantial economic benefits. Bridges et aI. (2000) conducted a randomized double-blind, placebo-controlled trial during two consecutive influenza seasons (1997 to 1998 and 1998 to 1999) among more than I, 100 workers younger than age 65 employed at a U.S. manufacturing facility. From 1997 to 1998, the vaccine differed from the predominant circulating viruses, and thus, vaccination did not reduce influenza-like illnesses, provider visits, or absenteeism. The net cost for the vaccinated group was $65.59 per person more than the placebo group. This cost was influenced by one individual in the vaccinated group who was hospitalized for pneumonia.
From 1998 to 1999, the vaccine virus and the wildtype virus were similar. The vaccinated group had fewer influenza-like illnesses (34%), provider visits (42%), and less absenteeism (32%). However, once the cost of the vaccine and its administration was included, the vaccine group still had a net cost of $11.17 compared to the placebo group.
One explanation for the difference between Bridges et aI. (2000) and Nichol et aI. (1995) findings was the three-times-higher case rate in the placebo group for the Nichol et aI. report. However, even if Bridges et aI. (2000) assumed a doubling of the case rate in their vaccine and placebo groups in the year of the good vaccine match, the maximum amount saved by the vaccination Note: RCT = randomized, double blind, placebo-control trial; TlV = trivalent inactivated vaccine; CBM = cost-benefit model;
LAIV-T=trivalent live cold adopted influenza vaccine program was only $2.36 per person. Bridges, Meltzer, and Thompson (200 I) suggested the cost effectiveness of a worksite influenza immunization program may not be high because the prevalence of influenza infection rates are generally less than 10% in the general population, and only once in every 10 years is there a poor antigenic match between the vaccine strain and the wild-type virus. Also, health care costs for influenza-like illnesses in healthy working adults is considerably less than among older adults or other high-risk populations. A series of letters to the editor in the Journal of the American Medical Association featured dialogue about the reasons for the disparate findings between the above two double-blind, placebo-controlled trials. Nichol (lOOlb) and Byrnes and Kelly (2001) suggested the primary reason for the lack of net savings reported by Bridges et al. (2001) was the low rate of absenteeism (0.6 days) instead of the 2 to 4 days of lost time per influenza illness reported by Nichol et al. (1995) . Inclusion of the MARCH 2005, VOL. 53, NO.3 latter would have resulted in a net savings. Nevertheless, a double-blind, placebo-controlled trial in health care workers indicated a similar low rate of absenteeism in the non-vaccinated group (Wilde et aI., 1999) . Demographically, the Bridges et al. (2000) study population also differed from Nichol et al (1995) because the former included a greater proportion of older male workers, which may have contributed to the lower absenteeism rates (Nichol et al., 200Ib) . Levy (1996) proposed an accounting model to estimate the net cost resulting from the difference between the cost of influenza prevention by immunization and the subsequent savings taking into account an efficacy rate of the vaccine, the coverage rate of vaccination, and an attack rate among non-immunized individuals. The Levy model is shown in the Sidebar. (1999) in their model was the loss of marginal added value in the calculation of avoided cost. The economic benefit in excess of the employee's labor cost (e.g., wages, benefits, social taxes) is the marginal added value. As Burckel et al. (1999) argued, employees are valuable to the employer because they create value above that of their own labor costs. Therefore, any loss of productivity due to absenteeism represents a decrease in added value to the employer. Their methodology indicated avoided costs would be the lowest for those hierarchical job cate-gories where the workplace absence of the next highest level of job category (i.e., a supervisory position) would have the least amount of influence on daily productivity of the lower hierarchical job category. In other words, the more independent the workers, the less likely the absence of others supervising them would have an effect on the worker's productivity. Burckel et al. (1999) also suggested that the marginal added value of an employee may be age-dependent within any hierarchical job category (e.g., young workers may require more supervision/assistance to be productive and therefore cost avoidance will be greater for their supervisors). Using their model for the 4,030 workers in the pharma-chemical company, they calculated a benefit-cost ratio of 2.5 to I for employee influenza immunizations. The per capita net benefit was $35 per vaccinated person. Several sensitivity analyses showed that the break-even point for the influenza immunization program would occur if the vaccine cost less than $45. Burckel et al. (1999) concluded that workplace environments with the greatest amount of inter-employee dependence accrued the most benefit from an influenza immunization program as 93% of the economic value of the vaccine in their model was due to avoided indirect costs.
COST-BENEFIT MODElS OF NON·HEALTH CARE WORKSITES

The Levy Model
Nichol (200 Ia) conducted a Monte Carlo simulation analysis (i.e., a spreadsheet simulation that randomly generates values for uncertain variables over and over to simulate a model) to assess the cost-benefit analysis of vaccinating healthy working adults against influenza (Decisioneering, 2004) . Basic model terms included: • Cost of vaccination (vaccine and administration). • Cost of potential side effects due to vaccination. • Costs averted due to vaccination including direct costs of health care averted due to fewer clinic visits and hospitalizations.
• Costs averted due to indirect savings of averted lost work time, lower rates of reduced work effectiveness, and preserved future earnings.
Probability distributions were created for the model variables defined as the best case and then the range (minimum, maximum) for each variable. For the clinical outcomes analyzed, influenza immunization of healthy working adults resulted in the following (rounded) estimates per 100 persons (95% confidence interval in parentheses): 6 (3 -9) fewer influenza illnesses; 12 (5 -25) fewer days of absenteeism; 4 (2 -7) fewer days of reduced work effectiveness; and 3 (I -5) fewer provider visits. The mean net savings due to vaccination was $13.66 with 95% of the simulations resulting in a mean net savings (95% probability interval between net savings of $32.97 to net costs of $2.18). Contributing negatively to the mean net savings were the direct costs of vaccination ($10.64) and the indirect costs of vaccination ($6.05). Contributing positively to the mean net savings was the direct health care costs ($3.99) and the indirect costs ($26.46) averted.
The cost model was most sensitive to the influenza illness rate, work absenteeism due to influenza, and hourly wages. There remained a 57% probability that a net savings from vaccination of $2.02 would still accrue with the worst possible scenario. Nichol et al. (2001a) concluded that the probability of a net savings per person would be most impacted by: • Cost of vaccine administration. • Type of vaccine versus circulating strain match. • Probability of lost work productivity (e.g., absenteeism). This represents approximately 80% of the costs averted because of vaccination.
Variables not considered in the Nichol et al. (2001a) simulation model that might further influence the findings include the workers' gender, job classification, income (related to job classification), and age.
A randomized, double-blind, placebo-controlled trial, multi-center study of 4,561 healthy, working adults (ages 18 to 64) assessed the clinical effectiveness of the LAIV-T (Nichol et al., 1999) . Using information from this study, Nichol, Mallon, and Mendelman (2003) subsequently conducted a cost-benefit analysis of these data.
Their cost-benefit model was net costs (savings) =[sum of vaccination costs] -[sum of averted costs].
Vaccination costs equals sum of: • Vaccine cost and administration. • Lost work time for vaccination including its potential side effects. • Direct costs for potential side effects of vaccine.
Averted costs equals sum of: • Averted health care costs. • Averted work loss costs avoided. • Averted impaired work productivity costs.
Using Monte Carlo simulation analyses, Nichol et al. (2003) estimated the mean break-even cost for the LAIV-T and its administration was $43. However, their cost-benefit analysis did not include the direct cost of the vaccine because it was unknown at the time. The manufacturer (MedImmune Inc., Gaithersburg, MD) vaccine (F1uMist®) cost is currently $23.50. At a cost of $26 for the vaccine and its administration, Nichol et al. estimated, in their Monte Carlo simulation analyses, a net savings 95% of the time with mean savings of approximately $18 per vaccinated individual. Employee wages, reduced work effectiveness, and work days lost were the most important predictors in their cost-benefit models. Depending on the age structure of the workplace population, the use of the LAIV-T may not be a practical vaccine option because the current indication for use is among individuals 5 to 49 years of age.
INSIGHTS INTO THE ADMINISTRATION OF A LARGE WORKSITE INFLUENZA IMMUNIZATION PROGRAM
During the past 10 years, an annual influenza immunization program has been conducted resulting in approximately 5,000 employees vaccinated within 3 to 4 days. Based on this program, it was determined that the first consideration for an efficient worksite influenza immunization program is its funding source. Will the program be fully covered by the employer's insurance program and defined as a preventive service? If so, is it considered part of the deductible?
Second, who will administer the influenza vaccine and when will it occur? This could be performed by on-site employed occupational health nurses, contracted professional services, or public health departments. Contracts must be signed early in the year to place an order for delivery of influenza vaccine in the fall. Time should also be allowed for legal review of these contracts. A mass immunization program requires sufficient staff to immunize 5,000 employees within 3 to 4 days. The immunization program occurs during the first or second week in November abiding with recommendations that higher risk populations (e.g., older adults) be immunized first in case of a vaccine shortage, as has occurred in the past.
Third, the influenza immunization program is advertised early in October generally coinciding with when the news media begins to report the need for influenza immunizations among high risk populations. At this time, explicit guidelines are given for immunization (e.g., employees only, no contractors or retirees, and eligibility from a health care standpoint). Pregnant employees may participate in the program with a written order from their personal physicians. At all times, a consistent message is given that the program is administered on a first-come, first-serve basis. No "make-up" individual immunization appointments will be offered by the company's occupational health service.
On the day of immunization, each employee must read and sign a consent form that provides information about the vaccine and potential complications. Because of the first-come, first-serve policy, the first day of immunization has always been the busiest time with more than 1,000 employees immunized in the first 2 hours of the first day, and an average wait of 15 minutes. Approximately 50% of all vaccinations were performed the first day. The first day of operation begins at 7 a.m. to minimize the wait because many employees wish to be vaccinated before they begin work.
On the remaining days, employees generally do not have wait time. Each employee is given an "I received my flu shot" sticker to further remind fellow employees of the program. Immunizations are performed by professional staff from the local public health department that contracted with the company to perform these services.
Absenteeism was evaluated among the employees who participated in the workplace influenza immunization program (Burris et al., 1999; Olsen et al., 1998) . There was a slight reduction in absenteeism among those who participated in the influenza program with the greatest reduction among female employees younger than age 50 with two or more children. These data suggest that any cost-benefit analysis from an employer-sponsored immunization program may not be uniform across employees' age, gender, health history, and home environment. Besides potential savings to the employer, employees reported satisfaction with the annual worksite influenza immunization program.
CONCLUSION
The primary costs to consider in the cost-benefit analysis of a worksite influenza immunization program are ,
IN SUMMARY
3 Efficient large worksite influenza immunization programs are feasible and worthy ofemployer consideration for economic and employee satisfaction reasons.
2 Based on several models published inthe literature, estimates ofsavings per healthy working adult employee could be anticipated to range between $15 and $50. Variations ofthis net savings are primarily based on assumptions ofproductivity estimates ofthe employee.
Worksite Influenza Immunization Programs
the vaccine cost and its administration, the efficacy of the vaccine, and the assumptions used to calculate lost productivity from worker absenteeism or decreased effectiveness. The primary savings are minimized lost productivity rather than the direct cost of the vaccine or costs associated with health care for those with influenza in the workplace. Depending on the models reviewed, estimates of savings per healthy working adult employee generally ranged between $15 and $50. Variation in savings exists because of the employer's productivity estimates of the employee.
